A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Status:
Completed
Trial end date:
2020-10-21
Target enrollment:
Participant gender:
Summary
The study is investigating the efficacy and safety of UroGen's UGN-102 to treat patients with
Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at intermediate risk of recurrence.